PMID- 33367927
OWN - NLM
STAT- MEDLINE
DCOM- 20211115
LR  - 20211204
IS  - 1791-2423 (Electronic)
IS  - 1019-6439 (Linking)
VI  - 58
IP  - 1
DP  - 2021 Jan
TI  - Critical role of mTOR in regulating aerobic glycolysis in carcinogenesis 
      (Review).
PG  - 9-19
LID - 10.3892/ijo.2020.5152 [doi]
AB  - Mammalian target of rapamycin (mTOR) serves an important role in regulating 
      various biological processes, including cell proliferation, metabolism, apoptosis 
      and autophagy. Among these processes, energy metabolism is the dominant process. 
      The metabolism of not only amino acids, fatty acids and lipids, but also that of 
      nucleotides and glucose has been indicated to be regulated by mTOR. Aerobic 
      glycolysis, which is a specific form of glucose metabolism, is prevalent in 
      carcinomas, and it has been considered to be a potential target for cancer 
      therapy. In reviewing the complexity of the mTOR pathway, it is important to 
      elucidate the central role and detailed pathway via which mTOR regulates 
      glycolysis. In the present study, the complex mechanisms via which mTOR regulates 
      aerobic glycolysis were comprehensively reviewed to highlight the potential of 
      drug development via targeting the molecules associated with mTOR and glycolysis 
      and to further provide strategies for the clinical treatment of cancer.
FAU - Fan, Hui
AU  - Fan H
AD  - Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia 
      Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 
      Jiangsu 210023, P.R. China.
FAU - Wu, Yuanyuan
AU  - Wu Y
AD  - Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia 
      Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 
      Jiangsu 210023, P.R. China.
FAU - Yu, Suyun
AU  - Yu S
AD  - Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia 
      Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 
      Jiangsu 210023, P.R. China.
FAU - Li, Xiaoman
AU  - Li X
AD  - Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia 
      Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 
      Jiangsu 210023, P.R. China.
FAU - Wang, Aiyun
AU  - Wang A
AD  - Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia 
      Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 
      Jiangsu 210023, P.R. China.
FAU - Wang, Shijun
AU  - Wang S
AD  - Shandong Co‑innovation Center of TCM Formula, College of TCM, Shandong University 
      of TCM, Jinan, Shandong 250355, P.R. China.
FAU - Chen, Wenxing
AU  - Chen W
AD  - Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia 
      Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 
      Jiangsu 210023, P.R. China.
FAU - Lu, Yin
AU  - Lu Y
AD  - Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia 
      Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 
      Jiangsu 210023, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201125
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology/therapeutic use
MH  - Carcinogenesis/drug effects/*metabolism
MH  - Cell Line, Tumor
MH  - Humans
MH  - Neoplasms/*drug therapy/metabolism/pathology
MH  - Signal Transduction/drug effects
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors/*metabolism
MH  - Warburg Effect, Oncologic/*drug effects
OTO - NOTNLM
OT  - mTOR
OT  - aerobic glycolysis
OT  - carcinogenesis
EDAT- 2020/12/29 06:00
MHDA- 2021/11/16 06:00
CRDT- 2020/12/28 12:18
PHST- 2020/06/20 00:00 [received]
PHST- 2020/11/09 00:00 [accepted]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/11/16 06:00 [medline]
PHST- 2020/12/28 12:18 [entrez]
AID - 10.3892/ijo.2020.5152 [doi]
PST - ppublish
SO  - Int J Oncol. 2021 Jan;58(1):9-19. doi: 10.3892/ijo.2020.5152. Epub 2020 Nov 25.